The twists and turns of Stephen Friend’s career are both dizzying and thrilling. In the early days, Stephen Friend, MD, PhD, CEO and co-founder of Sage Bionetworks, spent many a late night as a resident in the emergency room at Children’s Hospital of Philadelphia with Gary Fleischer, MD, current pediatrician-in-chief at Boston Children’s Hospital.
Friend later wound up at Boston Children’s as well, where he did his pediatric hematology-oncology fellowship and later, as part of the faculty, helped co-lead the team that identified the first tumor suppressor at Boston Children’s. A few years later, Friend left academia to pursue his passion in a startup and later engineered a landing at Sage Bionetworks, a nonprofit focused on patient engagement and open science in the research process. The Resilience Project, one of Sage’s research initiatives, analyzes DNA from healthy volunteers to discover rare mutations that protect resilient people from serious childhood illnesses.
Though Bruce Zetter, PhD, Charles Nowiszewski Professor of Cancer Biology in Boston Children’s Hospital’s Department of Surgery, has had a lifelong passion for science, he once toyed with an alternate career—as an actor. But he stuck with his love for science and pursued a career in academic medicine. Countless patients, students, business partners and mentees have benefitted from that decision.
Bruce Zetter, PhD, wears quite a few hats: Pioneer. Partner. Teacher. Mentor. Charles Nowiszewski Professor of Cancer Biology in Boston Children’s Hospital’s Department of Surgery.
Now, he’s adding crime fighter to the list. “The biggest crime in the health enterprise is when the next cure for Parkinson’s disease, cancer or multiple sclerosis is left on the bench because the researcher completed the discovery phase and decided that was enough,” he says. “So the breakthrough never becomes a drug or test.”
Gena Koufos, RN, MS, MBA, is program manager in Boston Children’s Hospital’s Innovation Acceleration Program. Her role entails designing new programs to support innovation acceleration across the institution. She offers resources and strategic guidance to cultivate and advance early stage innovators through product development and care delivery projects.
Learn more about the connection between nursing and innovation by exploring Koufos’ work and life. Click on the images and icons in the photo below to see what makes Koufos tick.
Single-Dose Cures for Malaria, Other Diseases (MIT Technology Review)
Pills that deliver a full course of treatment in one swallow could, or “super pills,” could simplify the treatment of diseases such as malaria and potentially produce cost savings that stretch into the $100 billion a year range, according to Bob Langer, PhD, from the Massachusetts Institute of Technology.
A Pancreas in a Capsule (MIT Technology Review)
Can stem cells solve the Type 1 diabetes puzzle? A handful of United States patients have had lab-grown pancreas cells, derived from human embryonic stem cells, transplanted in a human safety trial. Tech Review documents the challenges, and potential, of turning stem cells into real, functioning pancreas cells.
From a series profiling researchers and innovators at Boston Children’s Hospital
He’s a big thinker focused on harnessing the hyper-small. Daniel Kohane, MD, PhD, is a leading drug delivery and biomaterials researcher, leveraging nanoparticle technology and other new vehicles to make medications safer and more effective.
It’s not quite what he had in mind as a child. He dreamed of studying life forms in remote galaxies.
But when he became aware of the constraints of relativity, he re-focused his ambitions, ultimately concentrating on innovations in drug delivery. Here’s what he told us.
Daymond John, of ABC’s “Shark Tank,” and a five-judge panel of venture capitalists and physicians selected two winners in the Innovation Tank at the Boston Children’s Hospital Global Pediatric Innovation Summit + Awards. The judges awarded the fledgling companies—both of which have created products to help prevent catheter-associated infections—$12,500 each. The runner-up, Kurbo, received $5,000.
“What’s amazing about the Innovation Tank is that [the winners] don’t have to give up any of their company,” John said. The number-one reason new businesses don’t succeed is overfunding. That’s because aspiring entrepreneurs often take out substantial loans to fund their innovations.
Here’s a closer look at the three innovators who participated in the tank: